Citigroup’s IN8bio INAB Stock Holding History

Citigroup’s Portfolio INAB Stock Details INAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-49	Closed	-$106	–	6244
2025 Q3	$106	Buy	+49	New	+$108	﹤0.01%	5807

Other funds holding INAB

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BCM

BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TCBWMS

Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup's INAB Position: Q4 2025 in Review

Citigroup sold out of IN8bio (INAB) in Q4 2025, closing a stake of 49 shares — an estimated $106 sold.

Citigroup first reported a position in INAB in Q3 2025 and held it in 1 quarter. The position peaked at $106 in Q3 2025. 22 funds tracked by Wall St. Rank hold INAB as of Q4 2025.

Citigroup reported no remaining IN8bio position as of Q4 2025 after selling out during the quarter.
Citigroup sold 49 IN8bio shares in Q4 2025, an estimated $106.
Citigroup first reported a position in IN8bio in Q3 2025 and held it in 1 quarter.
Citigroup's IN8bio position peaked at $106 in Q3 2025.
22 funds tracked by Wall St. Rank held IN8bio as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.